MX2015008503A - Conjugados dirigidos encapsulados en particulas y sus formulaciones. - Google Patents

Conjugados dirigidos encapsulados en particulas y sus formulaciones.

Info

Publication number
MX2015008503A
MX2015008503A MX2015008503A MX2015008503A MX2015008503A MX 2015008503 A MX2015008503 A MX 2015008503A MX 2015008503 A MX2015008503 A MX 2015008503A MX 2015008503 A MX2015008503 A MX 2015008503A MX 2015008503 A MX2015008503 A MX 2015008503A
Authority
MX
Mexico
Prior art keywords
formulations
particles
methods
targeted conjugates
active agent
Prior art date
Application number
MX2015008503A
Other languages
English (en)
Other versions
MX360098B (es
Inventor
Rajesh Shinde
Mark T Bilodeau
Sudhakar Kadiyala
Brian White
Richard Wooster
Benoît Moreau
Timothy Edward Barder
Original Assignee
Blend Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blend Therapeutics Inc filed Critical Blend Therapeutics Inc
Publication of MX2015008503A publication Critical patent/MX2015008503A/es
Publication of MX360098B publication Critical patent/MX360098B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Han sido diseñadas partículas, incluyendo nanopartículas y micropartículas, y sus formulaciones farmacéuticas que contienen conjugados de un agente activo como un agente terapéutico, profiláctico o diagnóstico unido a una fracción dirigida por medio de un linker. Las partículas diseñadas proveen una liberación tempo-espacial mejorada del agente activo y/o una biodistribución mejorada. Los métodos para hacer los conjugados, las partículas, y sus formulaciones son proveídos. Los métodos para administrar las formulaciones a sujetos que las requieran son proveídos, por ejemplo, para tratar o prevenir cáncer o enfermedades infecciosas.
MX2015008503A 2012-12-28 2013-12-30 Conjugados dirigidos encapsulados en partículas y sus formulaciones. MX360098B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261746866P 2012-12-28 2012-12-28
PCT/US2013/078361 WO2014106208A1 (en) 2012-12-28 2013-12-30 Targeted conjugates encapsulated in particles and formulations thereof

Publications (2)

Publication Number Publication Date
MX2015008503A true MX2015008503A (es) 2016-01-22
MX360098B MX360098B (es) 2018-10-22

Family

ID=49998713

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008503A MX360098B (es) 2012-12-28 2013-12-30 Conjugados dirigidos encapsulados en partículas y sus formulaciones.

Country Status (14)

Country Link
US (5) US20140187501A1 (es)
EP (1) EP2938364A1 (es)
JP (2) JP6118914B2 (es)
KR (1) KR20150100706A (es)
CN (2) CN110179995A (es)
AU (2) AU2013369982B2 (es)
CA (1) CA2896571C (es)
HK (1) HK1217085A1 (es)
IL (1) IL238994B (es)
MX (1) MX360098B (es)
MY (1) MY172519A (es)
SG (2) SG11201504235UA (es)
WO (1) WO2014106208A1 (es)
ZA (1) ZA201504109B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
SG10201706618UA (en) 2012-11-15 2017-09-28 Endocyte Inc Conjugates for treating diseases caused by psma expressing cells
MY172519A (en) * 2012-12-28 2019-11-28 Tarveda Therapeutics Inc Solid polymeric controlled release nanoparticle
EP3495355A1 (en) 2013-10-18 2019-06-12 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10011622B2 (en) * 2013-12-31 2018-07-03 Placon Therapeutics, Inc. Compounds, compositions, and methods for the treatment of cancers
MX2017007018A (es) * 2014-12-01 2018-03-23 Innoup Farma S L Nanopartículas para encapsular compuestos, su preparación y sus usos.
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
CN107530291A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 双重负载的脂质体药物制剂
US9895313B2 (en) 2015-03-03 2018-02-20 Cureport, Inc. Combination liposomal pharmaceutical formulations
KR20180021742A (ko) * 2015-06-30 2018-03-05 타베다 세라퓨틱스, 인코포레이티드 표적화된 접합체 및 이의 입자 및 제형
CA2993429A1 (en) * 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
US20180258411A1 (en) * 2015-09-25 2018-09-13 Tarveda Therapeutics, Inc. Compositions and methods for genome editing
WO2017054907A1 (en) 2015-09-30 2017-04-06 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
US11065272B2 (en) 2015-10-06 2021-07-20 University Of Washington Oxygen reactive polymers for treatment of traumatic brain injury
EP3368546A4 (en) * 2015-10-28 2019-06-26 Tarveda Therapeutics, Inc. SSTR TARGETED CONJUGATES, AND ITS PARTICLES AND FORMULATIONS
CN106957422B (zh) * 2015-12-31 2020-07-07 南京绿叶制药有限公司 一种磷脂-聚乙二醇-psma配体化合物及其制备方法
WO2017147240A1 (en) 2016-02-23 2017-08-31 Tarveda Therapeutics, Inc. Hsp90 targeted conjugates and particles and formulations thereof
US10744212B2 (en) * 2016-03-14 2020-08-18 General Electric Company Topical application of nerve labeling dyes for image-guided surgery
EP3491374A4 (en) 2016-07-28 2020-03-25 Waters Technologies Corporation ENCLOSED PREANALYTIC WORKFLOWS FOR FLOW DEVICES, LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRIC ANALYZES
WO2018022957A1 (en) * 2016-07-29 2018-02-01 Tarveda Therapeutics, Inc. T cell binding conjugates and methods of use
AU2017376766A1 (en) * 2016-12-14 2019-06-06 Tva (Abc), Llc HSP90-targeting conjugates and formulations thereof
WO2018138607A1 (en) * 2017-01-24 2018-08-02 Nestec Sa Compositions comprising anti-fel d1 antibodies and methods for reducing at least one symptom of human allergy to cats
US11358994B2 (en) 2017-07-27 2022-06-14 Saint Louis University Fatty acid modified human epidermal growth factor
EP3706801A4 (en) * 2017-11-08 2022-04-06 L.E.A.F Holdings Group LLC PLATINUM COMPLEXES AND THEIR USES
CN112272519B (zh) * 2018-05-27 2023-01-06 以色列国家农业部、农村发展农业研究组织 用于生物杀虫剂的经由皮克林乳液的单个单元体封装
WO2019241853A1 (en) * 2018-06-21 2019-12-26 NanoMed Holdings Pty Ltd Platinum-based amphiphile prodrugs
US20210244822A1 (en) * 2018-06-25 2021-08-12 The Board Of Regents Of The University Of Oklahoma Conjugates with internal and terminal-end heparosan linkages
JP7425066B2 (ja) 2018-09-04 2024-01-30 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 核酸を臓器特異的送達するための組成物および方法
GB2592504B (en) 2018-09-04 2023-02-15 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
CN109289053B (zh) * 2018-09-30 2020-10-13 浙江大学 卡巴他赛-寡/聚乳酸偶联前药、制剂及其制备方法与应用
EP3989941A4 (en) * 2019-06-25 2023-05-10 Tva (Abc), Llc SSTR-TARGETING CONJUGATES AND RELATED FORMULATIONS
CN110974972B (zh) * 2019-12-03 2023-01-20 沈阳药科大学 难溶性药物的弱酸性衍生物及其脂质体制剂
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
KR20210116339A (ko) * 2020-03-16 2021-09-27 주식회사 바이오이즈 표적화 압타머 접합체를 캡슐화한 입자 및 이의 용도
CN111888332B (zh) * 2020-06-19 2023-07-25 杭州师范大学 一种卡巴他赛柔性乳剂及其制备方法
US11896713B2 (en) * 2020-10-22 2024-02-13 Rutgers, The State University Of New Jersey Strategies to enhance lung cancer treatment
CN113087787B (zh) * 2021-05-19 2023-03-21 广西医科大学第二附属医院(广西医科大学第二临床医学院) 一种蚯蚓血红蛋白分离及纯化方法
EP4282435A1 (en) * 2022-05-23 2023-11-29 Danmarks Tekniske Universitet Formulations of active pharmaceutical ingredients and excipients in icells via hydrophobic ion pairing

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049203A1 (en) * 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
US20030109682A1 (en) * 2001-09-07 2003-06-12 Daniel Santi Maytansines and maytansine conjugates
JP2006514698A (ja) * 2002-10-30 2006-05-11 スフェリックス， インコーポレイテッド ナノ粒子生物活性物質
US7232805B2 (en) * 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
WO2005118612A1 (en) * 2004-06-04 2005-12-15 Sonus Pharmaceuticals, Inc. Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs
PL216369B1 (pl) * 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
EP1700608A1 (en) * 2005-03-10 2006-09-13 Schering AG Chelators for radioactively labeled conjugates comprising a stabilizing sidechain
EP1745802A1 (en) * 2005-07-20 2007-01-24 Kreatech Biotechnology B.V. Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes
JP5630998B2 (ja) * 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
ES2376175T3 (es) * 2007-09-28 2012-03-09 Bind Biosciences, Inc. Direccionamiento a células de c�?ncer usando nanopart�?culas.
BRPI0818780A2 (pt) * 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
WO2009152440A1 (en) * 2008-06-13 2009-12-17 Cedars-Sinai Medical Center Small molecule ligand-drug conjugates for targeted cancer therapy
US20110105417A1 (en) * 2008-06-26 2011-05-05 The Curators Of The University Of Missouri Drug Conjugates
WO2010047765A2 (en) * 2008-10-20 2010-04-29 Massachussetts Institute Of Technology Nanostructures for drug delivery
US8470980B2 (en) * 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
KR102416359B1 (ko) * 2010-04-15 2022-07-01 코디악 사이언시스 인코포레이티드 고분자량 쌍성이온-함유 중합체
WO2012030745A1 (en) * 2010-08-30 2012-03-08 Access Pharmaecuticals, Inc MULTIVITAMIN TARGETING OF RNAi THERAPEUTICS
FR2967581B1 (fr) * 2010-11-19 2012-12-28 Sanofi Aventis Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques
CA2832480C (en) * 2011-04-07 2022-05-31 The Scripps Research Institute High-throughput screening for compounds modulating expression of cellular macromolecules
US20140308363A1 (en) * 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
MY172519A (en) * 2012-12-28 2019-11-28 Tarveda Therapeutics Inc Solid polymeric controlled release nanoparticle

Also Published As

Publication number Publication date
US20220288229A1 (en) 2022-09-15
MX360098B (es) 2018-10-22
CN110179995A (zh) 2019-08-30
SG10201705514WA (en) 2017-08-30
SG11201504235UA (en) 2015-07-30
KR20150100706A (ko) 2015-09-02
AU2013369982B2 (en) 2016-11-17
IL238994A0 (en) 2015-07-30
CA2896571C (en) 2017-11-21
EP2938364A1 (en) 2015-11-04
US20200121808A1 (en) 2020-04-23
JP2016505609A (ja) 2016-02-25
US20160074526A1 (en) 2016-03-17
CA2896571A1 (en) 2014-07-03
MY172519A (en) 2019-11-28
JP6118914B2 (ja) 2017-04-19
ZA201504109B (en) 2019-10-30
AU2017200510A1 (en) 2017-02-16
US20140187501A1 (en) 2014-07-03
AU2013369982A1 (en) 2015-06-18
JP2017105855A (ja) 2017-06-15
WO2014106208A1 (en) 2014-07-03
CN104936622A (zh) 2015-09-23
US20180021454A1 (en) 2018-01-25
IL238994B (en) 2019-07-31
HK1217085A1 (zh) 2016-12-23
CN104936622B (zh) 2019-05-28

Similar Documents

Publication Publication Date Title
MX2015008503A (es) Conjugados dirigidos encapsulados en particulas y sus formulaciones.
PH12017500023A1 (en) Targeted conjugates and particles and formulations thereof
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
EA033456B1 (ru) Конъюгаты антитело-лекарственное средство, содержащие пептидомиметические линкеры
MY166014A (en) Combination therapy methods for treating proliferative diseases
PH12016501171A1 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
MX2010003642A (es) Nanotecnologia de vacuna.
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
NZ710746A (en) Pyrrolobenzodiazepines and conjugates thereof
NZ710729A (en) Amatoxin derivatives
WO2012129112A3 (en) Use of intracellular enzymes for the release of covalently linked bioactives
IN2015DN03219A (es)
MX2012014079A (es) Lipidos biodegradables para la administracion de agentes activos.
IN2012DN06720A (es)
UA104320C2 (ru) Фармацевтическая композиция на основе митохондриально-адресованного антиоксиданта для применения в медицинской и ветеринарной офтальмологии
PH12017502392A1 (en) Targeted conjugates and particles and formulations thereof
EP3001813A4 (en) Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging
WO2011002852A3 (en) Pro-drug complexes and related methods of use
IN2014DN09418A (es)
WO2017210246A3 (en) Penicillamine conjugates and particles and formulations thereof
WO2012009703A3 (en) Targeted nanoparticles for cancer and other disorders
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MX2019004963A (es) Conjugados y particulas especificos del sstr y formulaciones de los mismos.
TR201109804A2 (tr) Tek dozlu inhalasyon cihazı.
WO2012177653A3 (en) Targeting the neuromuscular junction for treatment

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: WALMART APOLLO, LLC

FG Grant or registration